Clinical Trial Update: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a combination of chemotherapy, rituximab, and ixazomib citrate in adults with various aggressive B-cell lymphomas including Burkitt l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma Unclassifiable with Features Intermediate Between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Myc Gene Mutation
• Plasmablastic Lymphoma

Drugs mentioned

• Chemotherapy regimen
• Ixazomib citrate (Ixazomib)
• Rituximab (rituximab)

Snippet

Sponsor: Northwestern University | Conditions: Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN | Results posted: 2021-12-08